Impact of a Structured Report Template on the Quality of CT and MRI Reports for Hepatocellular Carcinoma Diagnosis
|
|
- Rudolph Tate
- 5 years ago
- Views:
Transcription
1 Impact of a Structured Report Template on the Quality of CT and MRI Reports for Hepatocellular Carcinoma Diagnosis Jeremy Ganeles 1, Tulay Ekinci 1, Milana Flusberg 1, Viktoriya Paroder 1, Mariya Kobi 1, Shlomit Goldberg-Stein 1, Victoria Chernyak 1 1 Montefiore Medical Center, Bronx, NY 1 The authors have no financial disclosures
2 Introduction LI-RADS developed in 2011 and updated in 2014 to standardize an algorithm and lexicon for interpretation and reporting of CT/MRIs in patients at risk for HCC Diagnostic algorithm based on defined major and ancillary imaging features, but no specific recommendations provided on how to report these features Structured reports has been shown to demonstrate greater clarity and comprehensive content when compared to free-text reports Similarly shown to be preferred by both referring clinicians and radiologist
3 Purpose To assess the impact of implementing a Liver Imaging Reporting and Data System (LI-RADS) structured reporting template on the quality of MRI reports for hepatocellular carcinoma
4 Methods: Background Structured LIRADS introduced at Montefiore in 4/2015; accompanied by LI- RADS training Template includes Observation identifier Location (Couinaud segment) Pick lists for all LI-RADS major features: Arterial Phase Hyperenhancement (APHE): yes/no Washout (WO): yes/no Capsule : yes/no Diameter Threshold Growth (TG): yes/no/n/a > Final LI-RADS category
5 LIRADS Template
6 Methods Retrospective IRB approved study Included reports of CTs and MRIs from 9/2014 to 2/2016 Free-text reports Structured LI-RADS reports Included only "Probable" and "Definite" HCC lesions (i.e. LR- 4 and LR-5) or equivalent descriptors in free-text reports Presence or absence of each or the following was recorded for each observation: LI-RADS category Couinaud segment Major LI-RADS HCC features: APHE WO Diameter Threshold growth Capsule At least one image number provided
7 Methods Free-text reports were compared with structured template report for whether presence or absence of each of the assessed variables was unequivocally reported Logistic regression models with binary outcomes of unequivocal reporting of each of the variables were constructed
8 Results Template (n=181) Free-text (n=125) p Value Age (years; mean and standard deviation) 63.0 (8.1) 63.6 (7.9) Sex (n, % male) 131 (72.4) 85 (68.0) Cause of liver disease (n, %) Hepatitis C Cirrhosis, NOS Hepatitis B Alcoholic cirrhosis Primary biliary cirrhosis Hepatitis C and B 99 (54.7) 65 (35.9) 9 (5.0) 5 (2.8) 0 (0.0) 3 (1.7) 87 (69.6) 26 (20.8) 3 (2.4) 7 (5.6) 2 (1.6) 0 (0.0) Modality (n, % MR) 164 (90.6) 100 (80.0) Description of lesion Definite HCC Probable HCC HCC Compatible with HCC Consistent with HCC Likely HCC Typical of HCC Suspicious for HCC Concerning for HCC 74 (40.9) 97 (53.6) 2 (1.1) 1 (0.6) 2 (1.1) 2 (1.1) 2 (1.1) 0 (0) 1 (0.6) 0 (0) 3 (2.4) 11 (8.8) 11 (8.8) 51 (40.8) 5 (4.0) 21 (16.8) 16 (12.8) 7 (5.6) <0.001
9 Results Variable Template (n=181) Free-text (n=125) p Value LI-RADS category 178 (98.3) 23 (18.4) <0.001 Couinaud segment 181 (100) 102 (81.6) <0.001 Diameter 181 (100) 118 (94.4) Presence/absence of TG 140 (77.4) 14 (11.2) <0.001 unequivocally reported Presence/absence of APHE 177 (97.8) 101 (80.8) <0.001 unequivocally reported Presence/absence of WO 178 (98.3) 93 (74.4) <0.001 unequivocally reported Presence/absence of capsule 176 (97.2) 24 (19.2) <0.001 unequivocally reported At least image number reported 181 (100) 81 (64.8) <0.001 Reported as n (%)
10 Results Outcome variable Odds Ratio 95% CI p Value LI-RADS category reported <0.001 Presence/absence of TG unequivocally <0.001 reported Presence/absence of APHE unequivocally reported <0.001 Presence/absence of WO unequivocally <0.001 reported Presence/absence of capsule unequivocally reported <0.001 Adjusted for modality and cause of liver disease; free-text group as the reference
11 Discussion Structured reporting demonstrated more comprehensive and consistent reporting of the major HCC features and LI-RADS category Serves as a useful checklist for assessing liver lesions in at-risk patients Documentation of major HCC features is mandated by OPTN (Organ Procurement and Transplantation Network) for transplant candidates All imaging is re-interpreted by radiologists in transplant centers Adds cost and time More likely to use a scoring system and characterize a lesion as definite HCC at transplant center Substantial differences shown in MRI interpretations between transplant center and outside institution reads Implementation of structured reporting may help reduce discrepancies in HCC diagnosis between readers with varying experience and comfort, as well as increase the rate of reporting of all OPTN-required elements, thereby eliminating the need for re-interpretation.
12 Discussion Limitations: Study limited to Definite or Probable HCC End user satisfaction was not assessed Impact on patient management/outcome was not assesed Accuracy of reports not reviewed Conclusion Use of structured LI-RADS template results in more comprehensive and consistent reporting of major features of HCC and LI-RADS category compared with free-text.
Objectives. LI-RADS v2017. Working Groups. Cynthia Santillan. Released October 2014 Diagnosis. Screening/ Surveillance. Diagnosis
LR-NC Cynthia Santillan LR-TIV Objectives 1. To teach participants how to apply the Liver Imaging Reporting and Data System () to their interpretation of imaging studies for the evaluation of hepatocellular
More informationTalking To Your Hepatologists & Colleagues About LI-RADS. Joseph Yacoub MD & Claude Sirlin MD SCBT-MR 2017 Workshop
Talking To Your Hepatologists & Colleagues About LI-RADS Joseph Yacoub MD & Claude Sirlin MD SCBT-MR 2017 Workshop What is LI-RADS? System for standardizing technique, interpretation, and reporting For
More informationManagement. Chapter 11. Primary Author. Contributing Authors. University of Toronto & University of Ottawa. Illustrators & figure contributors
Chapter 11 Primary Author Donald G. Mitchell Thomas Jefferson University Contributing Authors Victoria Chernyak Ania Z. Kielar Yuko Kono Claude B. Sirlin Montefiore Medical Center University of Toronto
More informationLI-RADS Reporting. Chapter 14. Primary Authors. Contributing Authors. Memorial Sloan Kettering Cancer Center
Chapter 14 LI-RADS Primary Authors Victoria Chernyak Mustafa R. Bashir Montefiore Medical Center Duke University Medical Center Contributing Authors Richard K. Do Aya Kamaya Ania Z. Kielar Donald G. Mitchell
More informationLiver Imaging Reporting and Data System LI-RADS v A Pictorial Review of the Categories on CT and MRI
Liver Imaging Reporting and Data System LI-RADS v2014 - A Pictorial Review of the Categories on CT and MRI Poster No.: C-1584 Congress: ECR 2017 Type: Educational Exhibit Authors: M. El Hawari, K. Ali,
More informationObjectives. HCC Incidence and Mortality. Disclosure Statement HCC. Imaging of Hepatocellular Carcinoma. Treatment of Hepatocellular Carcinoma
Imaging of Hepatocellular Carcinoma and the use of LI RADS Treatment of Hepatocellular Carcinoma Aaron D. Anderson, D.O. AOCR April 2015 Objectives Show how the use of LI RADS can simplify the diagnosis
More informationImaging-Based Diagnostic Systems for Hepatocellular Carcinoma
Gastrointestinal Imaging Review Cruite et al. Imaging-Based Diagnosis of Hepatocellular Carcinoma Gastrointestinal Imaging Review FOCUS ON: Irene Cruite 1 An Tang 2 Claude B. Sirlin 3 Cruite I, Tang A,
More informationCompute-aided Differentiation of Focal Liver Disease in MR Imaging
1063 Compute-aided Differentiation of Focal Liver Disease in MR Imaging Xuejun Zhang a, Masayuki Kanematsu b, Hiroshi Fujita c, Takeshi Hara c, Hiroshi Kondo b, Xiangrong Zhou c, Wenguang Li a and Hiroaki
More informationCT/MRI LI-RADS v2017 CORE
CT/MRI LI-RADS v2017 CORE Untreated observation without pathologic proof in patient at high risk for HCC If cannot be categorized due to image degradation or omission If definite tumor in vein (TIV) If
More informationDENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis
Quality ID #401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY
More informationDENOMINATOR: All patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis
Quality ID #401: Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis National Quality Strategy Domain: Effective Clinical Care Meaningful Measure Area: Preventive Care
More informationHCC and mass effect. Hepatocellular cancer: what if the AFP is rising but no lesion seen on imaging? What you need to know about AFP.
Hepatocellular cancer: what if the AFP is rising but no lesion seen on imaging? Arun J Sanyal M.B.B.S., M.D. Charles Caravati Professor of Medicine Virginia Commonwealth University Imaging features used
More informationLiver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic algorithm
pissn 2287-2728 eissn 2287-285X Liver Imaging Clinical and Molecular Hepatology 2016;22:296-307 Liver imaging reporting and data system (LI-RADS) version 2014: understanding and application of the diagnostic
More informationPEER-REVIEW REPORT CLASSIFICATION LANGUAGE EVALUATION SCIENTIFIC MISCONDUCT CONCLUSION. [ Y] Accept [ ] Grade B: Very good
Reviewer s code: 03656588 Reviewer s country: China Date reviewed: 2017-06-08 [ ] Grade A: Excellent [ Y] Accept [ ] Grade B: Very good [ ] High priority for [ Y] Grade C: Good language [ ] Major revision
More informationMRI for HCC surveillance and reporting: LI-RADS. Donald G. Mitchell, M.D. Thomas Jefferson University Philadelphia, PA
MRI for HCC surveillance and reporting: LI-RADS Donald G. Mitchell, M.D. Thomas Jefferson University Philadelphia, PA Cirrhotic Nodules Regenerative Nodule Atypical Nodule Hyperplastic Nodule Dysplastic
More informationHepatobiliary Malignancies Retrospective Study at Truman Medical Center
Hepatobiliary Malignancies 206-207 Retrospective Study at Truman Medical Center Brandon Weckbaugh MD, Prarthana Patel & Sheshadri Madhusudhana MD Introduction: Hepatobiliary malignancies are cancers which
More informationModern liver imaging techniques - A new era in liver ultrasound
Modern liver imaging techniques - A new era in liver ultrasound Yuko Kono, M.D., Ph.D. Clinical Professor Departments of Medicine and Radiology University of California, San Diego San Diego, USA How to
More informationLiver imaging reporting and data system: An expert consensus statement
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2017 Liver imaging reporting and data system: An expert consensus statement Khaled M. Elsayes The University of
More informationGastrointestinal Imaging Original Research
Gastrointestinal Imaging Original Research Potretzke et al. iphenotypic Primary Liver Carcinoma Gastrointestinal Imaging Original Research FOCUS ON: Theodora. Potretzke 1 enjamin R. Tan 2 Maria. Doyle
More informationUS LI-RADS v2017 CORE
US LI-RADS v2017 CORE Screening or surveillance US in patient at high risk for HCC US category US-1 US-2 US-3 Negative Subthreshold Positive Category Concept Definition US-1 Negative US-2 Subthreshold
More informationLIVER IMAGING TIPS IN VARIOUS MODALITIES. M.Vlychou, MD, PhD Assoc. Professor of Radiology University of Thessaly
LIVER IMAGING TIPS IN VARIOUS MODALITIES M.Vlychou, MD, PhD Assoc. Professor of Radiology University of Thessaly Hepatocellular carcinoma is a common malignancy for which prevention, screening, diagnosis,
More informationWith recent advances in treatment of hepatocellular SPECIAL ARTICLE
SPECIAL ARTICLE LI-RADS (Liver Imaging Reporting and Data System): Summary, Discussion, and Consensus of the LI-RADS Management Working Group and Future Directions Donald G. Mitchell, 1 Jordi Bruix, 2
More informationAMSER Case of the Month: June 2018
AMSER Case of the Month: June 2018 64 year old male undergoing evaluation for liver transplant By Timothy Morgan, MS IV Lake Erie College of Osteopathic Medicine Jonathan Potts, MD Interventional Radiology,
More informationNewcastle HPB MDM updated radiology imaging protocol recommendations. Author Dr John Scott. Consultant Radiologist Freeman Hospital
Newcastle HPB MDM updated radiology imaging protocol recommendations Author Dr John Scott. Consultant Radiologist Freeman Hospital This document is intended as a guide to aid radiologists and clinicians
More information9/10/2018. Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? DISCLOSURES
UCSF Transplant 2018: Pioneering Advances in Transplantation DISCLOSURES Liver Transplant for Hepatocellular Carcinoma (HCC): What is New? I have no relevant commercial interests or relationships to report
More informationPeer Review in Radiology
Department of Radiology Massachusetts General Hospital Harvard Medical School Peer Review in Radiology Hani Abujudeh MD, MBA Associate Professor of Radiology Harvard Medical School Massachusetts General
More informationNHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE LIVER ADVISORY GROUP UPDATE ON THE HCC DOWN-STAGING SERVICE EVALUATION
NHS BLOOD AND TRANSPLANT ORGAN DONATION AND TRANSPLANTATION DIRECTORATE LIVER ADVISORY GROUP UPDATE ON THE HCC DOWN-STAGING SERVICE EVALUATION 1. A service development evaluation to transplant down-staged
More informationSurveillance for Hepatocellular Carcinoma
Surveillance for Hepatocellular Carcinoma Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded on April
More informationImproved Detection of Clinically Significant Prostate Cancer Using a Structured Prostate Imaging Reporting Data System (PI-RADS) Template
Improved Detection of Clinically Significant Prostate Cancer Using a Structured Prostate Imaging Reporting Data System (PI-RADS) Template Abstract #17-130 ACR Annual Meeting 2017 Presenting Author: Whitney
More informationValidation of Clinical Outcomes in Electronic Data Sources
Validation of Clinical Outcomes in Electronic Data Sources Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Center for Clinical Epidemiology and Biostatistics Center for Pharmacoepidemiology
More informationThe Focal Hepatic Lesion: Radiologic Assessment
The Focal Hepatic Lesion: Radiologic Assessment Kevin Kuo, Harvard Medical School Year III Our Patient: PS 67 y/o female w/ long history of alcohol use Drinking since age 18, up to one bottle of wine/day
More informationReinterpretation of Outside Hospital MRI Abdomen Examinations in Patients With Cirrhosis: Is the OPTN Mandate Necessary?
Gastrointestinal Imaging Original Research Rahman et al. Reinterpretation of MRI Examinations in Cirrhosis Gastrointestinal Imaging Original Research W. Tania Rahman 1, 2 Hero K. Hussain 3 Neehar D. Parikh
More informationCritical Review Form Clinical Decision Analysis
Critical Review Form Clinical Decision Analysis An Interdisciplinary Initiative to Reduce Radiation Exposure: Evaluation of Appendicitis in a Pediatric Emergency Department with Clinical Assessment Supported
More informationHepatic Imaging: What Every Practitioner Should Know
Hepatic Imaging: What Every Practitioner Should Know Shuchi K. Rodgers, MD Section Chief, Abdominal Imaging Director of Ultrasound Department of Radiology Einstein Medical Center rodgerss@einstein.edu
More informationRepeatability of Diagnostic Features and Scoring Systems for Hepatocellular Carcinoma by Using MR Imaging 1
Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Original Research
More informationHEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT
HEPATOCELLULAR CARCINOMA: SCREENING, DIAGNOSIS, AND TREATMENT INTRODUCTION: Hepatocellular carcinoma (HCC): Fifth most common cancer worldwide Third most common cause of cancer mortality In Egypt: 2.3%
More informationLI-RADS v2016 Key Dates
Key Dates April 2014: ACR CEUS LI-RADS working group was formed Chair: Yuko Kono, Co-chair: Andrej Lyshchik Members: David Cosgrove, Christoph Dietrich, Hyun-Jung Jang, Tae Kim, Fabio Piscaglia, Claude
More informationTimothy L. Miao 1, Ania Z. Kielar 2,3, Rebecca M. Hibbert 2, Nicola Schieda 2,3
DOES LESION T1 SIGNAL INTENSITY RELATIVE TO LIVER PARENCHYMA PREDICT VISIBILITY ON ULTRASOUND? A clinical tool to determine feasibility of ultrasound-guided percutaneous interventions Timothy L. Miao 1,
More informationSpiculated breast masses on MRI: Which category should we choose, 4 or 5?
Spiculated breast masses on MRI: Which category should we choose, 4 or 5? Poster No.: C-1394 Congress: ECR 2015 Type: Scientific Exhibit Authors: N. Onishi, S. Kanao, M. Kataoka, M. Kawai, M. Iima, A.
More informationEffective Health Care Program
Comparative Effectiveness Review Number 143 Effective Health Care Program Techniques for the Diagnosis and Staging of Hepatocellular Carcinoma Executive Background and Objectives Hepatocellular carcinoma
More informationAlice Fung, MD Oregon Health and Science University
Alice Fung, MD Oregon Health and Science University Disclosure Comments The speaker Alice Fung, MD Has relevant financial relationships to disclose. Received honorarium from (Guerbet). This individual
More informationDiagnosis of Liver Tumor Using 3D Segmentation Method for Selective Internal Radiation Therapy
Diagnosis of Liver Tumor Using 3D Segmentation Method for Selective Internal Radiation Therapy K. Geetha & S. Poonguzhali Department of Electronics and Communication Engineering, Campus of CEG Anna University,
More informationSCBT-MR 2015 LungRADS : Basics
SCBT-MR 2015 LungRADS : Basics Reginald F. Munden MD, DMD, MBA I have no conflicts of interest to report National Lung Cancer Screening Trial 20% lung cancer mortality reduction 6.9% all cause mortality
More informationCritical reading of diagnostic imaging studies. Lecture Goals. Constantine Gatsonis, PhD. Brown University
Critical reading of diagnostic imaging studies Constantine Gatsonis Center for Statistical Sciences Brown University Annual Meeting Lecture Goals 1. Review diagnostic imaging evaluation goals and endpoints.
More informationHepatocellular carcinoma
Hepatocellular carcinoma Mary Ann Y. Huang, M.D., M.S., FAASLD Transplant hepatologist Peak Gastroenterology Associates Porter Adventist Hospital Denver, Colorado Background - Worldwide Hepatocellular
More informationThe Diagnosis of Hypovascular Hepatic Lesions Showing Hypo-intensity in the Hepatobiliary Phase of Gd-EOB- DTPA-enhanced MR Imaging in High-risk
2013 67 4 239 244 The Diagnosis of Hypovascular Hepatic Lesions Showing Hypo-intensity in the Hepatobiliary Phase of Gd-EOB- DTPA-enhanced MR Imaging in High-risk Patients for Hepatocellular Carcinoma
More informationHepatocellular Carcinoma: Diagnosis and Management
Hepatocellular Carcinoma: Diagnosis and Management Nizar A. Mukhtar, MD Co-director, SMC Liver Tumor Board April 30, 2016 1 Objectives Review screening/surveillance guidelines Discuss diagnostic algorithm
More informationPrevalence of adrenal incidentaloma a methodologic comparison of EMR query strategies
Prevalence of adrenal incidentaloma a methodologic comparison of EMR query strategies Michio Taya, BA 1 ; Viktoriya Paroder, MD, PhD 2 ; Eran Bellin, MD 3,4 ; Linda Haramati, MD, MS 2,3 2 Departments of
More informationGemstone Spectral Imaging quantifies lesion characteristics for a confident diagnosis
GE Healthcare Gemstone Spectral Imaging quantifies lesion characteristics for a confident diagnosis CT clinical case study lesion characterization Desiree Morgan, MD Vice Chair of Clinical Research Professor
More informationScreening for Hepatoma and an Introduction to LIRADS
Screening for Hepatoma and an Introduction to LIRADS Helena Gabriel, MD Associate Professor of Radiology Director, School of Ultrasound rthwestern University Feinberg School of Medicine Chicago, IL Overview
More information2/21/2014. Disclosure statement CT, MRI, LI-RADS. CT and MRI as first-line modalities PLAN. CT- and MRI-based diagnosis. Role of CT and MRI
Ancillary features that may favor HCC LR1 LR2 LR3 LR4 LR5 Ancillary features that may favor benignity,, LI-RADS An Tang, MD, MSc CHUM, University of Montreal CASL HCC Meeting: Consensus, Controversies
More informationAlexander Lankowski 1, Cedric Bien 1,2, Richard Silvera 1,2, Viraj Patel 1, Uriel Felsen 3, Oni Blackstock 1
Alexander Lankowski 1, Cedric Bien 1,2, Richard Silvera 1,2, Viraj Patel 1, Uriel Felsen 3, Oni Blackstock 1 1 Division of General Internal Medicine, Montefiore Health System & Albert Einstein College
More informationThe Management of Advanced Stage Hepatocellular Carcinoma
The Management of Advanced Stage Hepatocellular Carcinoma Pierce K.H Chow MD PhD Professor, Duke-NUS Graduate Medical School Singapore Senior Consultant Surgeon, National Cancer Center Singapore Senior
More informationThe pediatric end-stage liver disease (PELD) score
Selection of Pediatric Candidates Under the PELD System Sue V. McDiarmid, 1 Robert M. Merion, 2 Dawn M. Dykstra, 2 and Ann M. Harper 3 Key Points 1. The PELD score accurately predicts the 3 month probability
More informationHepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary)
Hepatocellular Carcinoma HCC Updated November 2015 by: Dr. Mohammed Alghamdi (Medical Oncology Fellow, University of Calgary) Staff Reviewers: Dr. Yoo Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer
More informationHCC Imaging and Advances in Locoregional Therapy. David S. Kirsch MD Ochsner Clinic Foundation
HCC Imaging and Advances in Locoregional Therapy David S. Kirsch MD Ochsner Clinic Foundation -Nothing to disclose Hepatic Imaging Primary imaging modalities include: US CT MR Angiography Nuclear medicine
More informationEvaluation Process for Liver Transplant Candidates
Evaluation Process for Liver Transplant Candidates 2 Objectives Identify components of the liver transplant referral to evaluation Describe the role of the liver transplant coordinator Describe selection
More informationDiscrepancy between the nonautomatic
Discrepancy between the nonautomatic and semiautomatic measurements of AAA diameter-does it influence outcome? Joy Roy Department of Vascular Surgery Karolinska University Hospital / Karolinska Institutet
More informationSurveillance for HCC Who, how Diagnosis of HCC Surveillance for HCC in Practice
Surveillance for Hepatocellular Carcinoma Hashem B. El-Serag, MD, MPH Dan L. Duncan Professor of Medicine Chief, Gastroenterology and Hepatology Houston VA & Baylor College of Medicine Houston, TX Outline
More informationStructured Reporting of Multiphasic CT for Hepatocellular Carcinoma: Effect on Staging and Suitability for Transplant
Gastrointestinal Imaging Original Research Poullos et al. Multiphasic CT Reporting for HCC Gastrointestinal Imaging Original Research Peter D. Poullos 1 Joseph J. Tseng 1 Marc L. Melcher 2 Waldo Concepcion
More informationSIR- RFS Journal Primer
Comparison of Combina-on Therapies in the Management of Hepatocellular Carcinoma: Transarterial Chemoemboliza-on with Radiofrequency Abla-on versus Microwave Abla-on SIR- RFS Journal Primer Quick Summary
More informationStaging & Current treatment of HCC
Staging & Current treatment of HCC Dr.: Adel El Badrawy Badrawy; ; M.D. Staging & Current ttt of HCC Early stage HCC is typically silent. HCC is often advanced at first manifestation. The selective ttt
More informationLiver Tumors. Prof. Dr. Ahmed El - Samongy
Liver Tumors Prof. Dr. Ahmed El - Samongy Objective 1. Identify the most important features of common benign liver tumors 2. Know the risk factors, diagnosis, and management of hepatocellular carcinoma
More informationWorkup of a Solid Liver Lesion
Workup of a Solid Liver Lesion Joseph B. Cofer MD FACS Chief Quality Officer Erlanger Health System Affiliate Professor of Surgery UTHSC-Chattanooga I have no financial or other relationships with any
More informationCopyright 2007 IEEE. Reprinted from 4th IEEE International Symposium on Biomedical Imaging: From Nano to Macro, April 2007.
Copyright 27 IEEE. Reprinted from 4th IEEE International Symposium on Biomedical Imaging: From Nano to Macro, April 27. This material is posted here with permission of the IEEE. Such permission of the
More informationLiver Transplantation Evaluation: Objectives
Liver Transplantation Evaluation: Essential Work-Up Curtis K. Argo, MD, MS VGS/ACG Regional Postgraduate Course Williamsburg, VA September 13, 2015 Objectives Discuss determining readiness for transplantation
More informationLocoregional Therapy for Hepatoma
Locoregional Therapy for Hepatoma Robert D. Crane, MD Interventional Radiology Virginia Mason How do we know a liver mass is HCC? HCC : Bx Of pts getting liver transplant only ~ 5% had Bx to establish
More informationRadiation burden of hepatocellular carcinoma screening program in hepatitis B virus patients should we recommend magnetic resonance imaging instead?
Radiation burden of hepatocellular carcinoma program in hepatitis B virus patients should we recommend magnetic resonance imaging instead? Background: Current Hepatocellular Carcinoma (HCC) surveillance
More informationLiver resection for HCC
8 th LIVER INTEREST GROUP Annual Meeting Cape Town 2017 Liver resection for HCC Jose Ramos University of the Witwatersrand Donald Gordon Medical Centre The liver is almost unique in that treatment of the
More informationNeed for long-term evaluation of therapy in Chronic Hepatitis B
Need for long-term evaluation of therapy in Chronic Hepatitis B VHPB meeting Budapest 18/03/2010 Solko Schalm & Mehlika Toy Licensed Therapy Chronic hepatitis B Drug Date of Efficacy Disease Clinical Mortality
More informationPatient referral for elective coronary angiography: challenging the current strategy
Patient referral for elective coronary angiography: challenging the current strategy M. Santos, A. Ferreira, A. P. Sousa, J. Brito, R. Calé, L. Raposo, P. Gonçalves, R. Teles, M. Almeida, M. Mendes Cardiology
More informationJesse Civan, M.D. Medical Director, Jefferson Liver Tumor Center
Liver Tumors Jesse Civan, M.D. Medical Director, Jefferson Liver Tumor Center Differential Diagnosis Malignant Metastatic from non-hepatic primary Hepatocellular carcinoma Cholangiocarcinoma Biliary cystcarcinoma
More informationUS-Guided Radiofrequency Ablation of Hepatic Focal Lesions
US-Guided Radiofrequency Ablation of Hepatic Focal Lesions Poster No.: C-2219 Congress: ECR 2011 Type: Scientific Exhibit Authors: D. Armario Bel, A. PLA, F. TERREL, X. Serres; BARCELONA/ES Keywords: Neoplasia,
More informationDisparities in Liver Transplant Allocation: An Update on MELD Allocation System
Disparities in Liver Transplant Allocation: An Update on MELD Allocation System Naudia L. Jonassaint, MD MHS Assistant Professor of Medicine and Surgery University of Pittsburgh School of Medicine Historical
More informationMSK MRI Protocol Standardization:
MSK MRI Protocol Standardization: Impact on patient care and finances across a large health care system Manickam Kumaravel, M.D. Thomas Connors, B.B.A. No financial disclosures Purpose To evaluate the
More informationResource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430
Putting NICE guidance into practice Resource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430 Published: January 2017 Summary Sofosbuvir velpatasvir is recommended as an option
More informationCurrent Guidelines for the Diagnosis and Management of Hepatocellular Carcinoma: A Comparative Review
Gastrointestinal Imaging Review rslanoglu et al. Guidelines on Hepatocellular Carcinoma Gastrointestinal Imaging Review tilla rslanoglu 1 deel R. Seyal Faezeh Sodagari zize Sahin Frank H. Miller Riad Salem
More informationEASL-EORTC Guidelines
Pamplona, junio de 2008 CLINICAL PRACTICE GUIDELINES: PARADIGMS IN MANAGEMENT OF HCC EASL-EORTC Guidelines Bruno Sangro Clínica Universidad de Navarra. CIBERehd. Pamplona, Spain Levels of Evidence according
More informationDefinition: Active injection drug users - Those who have injected any drug(s) within the 12 month reporting period
Quality ID #387 (NQF 3060): Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL
More information간암의조직검사 : 언제, 어떻게? 계명대학교의과대학내과학교실 정우진
간암의조직검사 : 언제, 어떻게? 계명대학교의과대학내과학교실 정우진 간생검한다 vs 안한다? M/81 Alcoholic LC, albumin 4.0, bil 0.6, Cr 1.06, glucose 141, afp 2.2, CA19-9 12.41 CT: R/O HCC in S8, R/O CC M/69 HBV(-), HCV(-), social alcoholics
More informationCT-MRI LI-RADS v2017: A Comprehensive Guide for Beginners
Review Article CT-MRI LI-RADS v2017: A Comprehensive Guide for Beginners Francesca Patella 1, Filippo Pesapane* 1, Enrico Maria Fumarola 1, Ilaria Emili 1, Riccardo Spairani 1, Salvatore Alessio Angileri
More informationInterventional Radiology in Liver Cancer. Nakarin Inmutto MD
Interventional Radiology in Liver Cancer Nakarin Inmutto MD Liver cancer Primary liver cancer Hepatocellular carcinoma Cholangiocarcinoma Metastasis Interventional Radiologist Diagnosis Imaging US / CT
More informationContrast Enhanced Ultrasound of Parenchymal Masses in Children
Contrast Enhanced Ultrasound of Parenchymal Masses in Children Sue C Kaste, DO On behalf of Beth McCarville, MD St. Jude Children s Research Hospital Memphis, TN Overview Share St. Jude experience with
More informationLiver imaging takes a step forward with Ingenia
Publication for the Philips MRI Community ISSUE 49 2013 / 2 Liver imaging takes a step forward with Ingenia Lyon South Hospital strives to move from several studies first CT, then MR or PET to using just
More informationComputer based delineation and follow-up multisite abdominal tumors in longitudinal CT studies
Research plan submitted for approval as a PhD thesis Submitted by: Refael Vivanti Supervisor: Professor Leo Joskowicz School of Engineering and Computer Science, The Hebrew University of Jerusalem Computer
More informationFinancial Disclosure
Benign Liver Masses Adil Abdalla, MBBS Creighton University-CHI Health August 25, 2018 Financial Disclosure Nothing to disclose Financial Disclosure 1 Objectives To assess patients with benign liver tumors
More informationHepatocellular Carcinoma Surveillance
Amit G. Singal, MD, MS Hepatocellular Carcinoma Surveillance Postgraduate Course: Challenges in Management of Common Liver Diseases 308 1 Patient Case 69 year-old otherwise healthy male with compensated
More informationOutreach Invitations Improve HCC Surveillance Rates: Results Of A Randomized Controlled Trial
Outreach Invitations Improve HCC Surveillance Rates: Results Of A Randomized Controlled Trial Amit G. Singal MD MS UT Southwestern Medical Center and Parkland Health & Hospital System Dallas, TX, USA 1
More informationScreening Programs background and clinical implementation. Denise R. Aberle, MD Professor of Radiology and Engineering
Screening Programs background and clinical implementation Denise R. Aberle, MD Professor of Radiology and Engineering disclosures I have no disclosures. I have no conflicts of interest relevant to this
More informationHEPATOCYTE SPECIFIC CONTRAST MEDIA: WHERE DO WE STAND?
HEPATOCYTE SPECIFIC CONTRAST MEDIA: WHERE DO WE STAND? Andrew T. Trout, MD @AndrewTroutMD Disclosures No relevant disclosures Outline Review of hepatocyte specific contrast media Review of hepatocellular
More informationLong-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance
Long-term Clinical Outcomes and Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with HBsAg Seroclearance Gi-Ae Kim, Han Chu Lee *, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim,
More informationLI-RADS Populations: Surveillance, Diagnosis, Staging, Treatment Response
Chapter 2 LI-RADS Populations: Surveillance, Diagnosis, Staging, Treatment Response Primary Author An Tang University of Montreal Contributing Authors Victoria Chernyak Oussama Hallouch Aya Kamaya Claude
More informationAllinaHealthSystems 1
Disclosure I have no financial relationships to disclose. Dimensions in Oncology 2017 Liver Cancers Jill May, BSN, RN, OCN Hepatobiliary Cancer Care Coordinator 1 LIVER ~ Where and what is it? Located
More informationTHE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA (HCC)
MEETING SUMMARY EASL 2017, AMSTERDAM, THE NETHERLANDS APRIL 19 TH TO 23 RD 2017 DR JEAN-CHARLES NAULT JEAN VERDIER HOSPITAL, BONDY, FRANCE THE CHANGING LANDSCAPE IN THE TREATMENT OF HEPATOCELLULAR CARCINOMA
More informationFAQs for HCP segment New Instructions for Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System Non-Adjunctive Indication
FAQs for HCP segment New Instructions for Dexcom G5 Mobile Continuous Glucose Monitoring (CGM) System Non-Adjunctive Indication Q1. The Dexcom G5 Mobile System is the first CGM System to receive FDA approval
More informationMultiple Primary Quiz
Multiple Primary Quiz Case 1 A 72 year old man was found to have a 12 mm solid lesion in the pancreatic tail by computed tomography carried out during a routine follow up study of this patient with adult
More informationDiagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Diagnosis, Staging and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases Jorge A. Marrero, MD, MS, MSHM; Laura M. Kulik, MD; Claude
More informationHepatocellular carcinoma in Sri Lanka - where do we stand?
SCIENTIFIC ARTICLE Hepatocellular carcinoma in Sri Lanka - where do we stand? R.C. Siriwardana 1, C.A.H. Liyanage 1, M.B. Gunethileke 2 1. Specialist Gastrointestinal and Hepatobilliary Surgeon, Senior
More informationComputer-Aided Evaluation of Malignancy with Magnetic Resonance Imaging of the Breast. Original Policy Date
MP 6.01.36 Computer-Aided Evaluation of Malignancy with Magnetic Resonance Imaging of the Breast Medical Policy Section Radiology Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed
More informationNon-Alcoholic Fatty Liver Disease
Non-Alcoholic Fatty Liver Disease None Disclosures Arslan Kahloon M.D Chief, Division of Gastroenterology and Hepatology University of Tennessee College of Medicine Chattanooga Objectives Understand the
More information